墙上的miR,miR,谁是最恶性的髓母细胞瘤miR?
本文综述了微小RNA(miRNA)在髓母细胞瘤中的作用,指出尽管已识别出4个具有不同生物学、遗传学和转录特征的分子亚组,但关于miRNA的研究大多仍集中于单一疾病临床实体而非分子亚组。本文旨在将大量miRNA研究工作置于髓母细胞瘤亚组框架中,以激发包括潜在治疗在内的新研究领域。
要点
- miRNA广泛调控大规模基因表达,在正常发育中起关键作用,其异常表达与癌症相关。
- 髓母细胞瘤的特征包括增殖增加、凋亡抑制和干性程序维持,这些特征受miRNA表达模式改变调控。
- 过去5年识别出4个具有不同生物学、遗传学和转录特征的分子亚组,但miRNA研究大多未按亚组区分。
核心结论
- 本综述旨在将大量关于miRNA的研究工作置于髓母细胞瘤亚组的框架内,以激发包括潜在治疗在内的新研究领域。
研究设计与样本
- 综述类文章,未报告系统检索范围。
主要发现
- 髓母细胞瘤的特征包括增殖增加、凋亡抑制和干性程序维持,这些特征受miRNA表达模式改变的调控。
- 过去5年识别出4个具有不同生物学、遗传学和转录特征的分子亚组,彻底改变了髓母细胞瘤研究领域。
- 尽管已有大量关于miRNA在髓母细胞瘤中作用的研究,但这些研究大多集中于单一疾病的临床实体,而非分子亚组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
microRNAs (miRNAs) have wide-ranging effects on large-scale gene regulation. As such, they play a vital role in dictating normal development, and their aberrant expression has been implicated in cancer. There has been a large body of research on the role of miRNAs in medulloblastoma, the most common malignant brain tumor of childhood. The identification of the 4 molecular subgroups with distinct biological, genetic, and transcriptional features has revolutionized the field of medulloblastoma research over the past 5 years. Despite this, the growing body of research on miRNAs in medulloblastoma has largely focused on the clinical entity of a single disease rather than the molecular subgroups. This review begins by highlighting the role of miRNAs in development and progresses to explore their myriad of implications in cancer. Medulloblastoma is characterized by increased proliferation, inhibition of apoptosis, and maintenance of stemness programs-features that are inadvertently regulated by altered expression patterns in miRNAs. This review aims to contextualize the large body of work on miRNAs within the framework of medulloblastoma subgroups. The goal of this review is to stimulate new areas of research, including potential therapeutics, within a rapidly growing field.
引用
- Wang X, Holgado BL, Ramaswamy V, et al. miR miR on the wall, who's the most malignant medulloblastoma miR of them all? Neuro Oncol. 2018. PMID: 28575493. doi:10.1093/neuonc/nox106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。